Navigation Links
OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
Date:8/29/2012

SAN DIEGO, Aug. 29, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its ImmunoPulse and NeoPulse therapies to treat solid tumor cancers, announced it will be presenting at the Rodman & Renshaw 2012 Annual Global Investment Conference in New York City.

Punit Dhillon, President and CEO of OncoSec, will deliver the Company presentation to conference attendees on Monday, September 10 at 3:15 PM ET in the Palm Room at the Waldorf Astoria Hotel. The presentation will also be webcast and can be viewed at this link: http://www.wsw.com/webcast/rrshq22/oncs

Mr. Dhillon said, "Presenting at the Rodman & Renshaw Global Investment Conference provides us an exciting opportunity to highlight our growing investment potential and leadership in the development of cancer therapies."

More than 300 public and private companies from around the world are registered to present in front of an audience of over 3,000 attendees. Newt Gingrich, 58th Speaker of the U.S. House of Representatives, will open the Conference as the Keynote Speaker on Monday, September 10. Conference registration details can be found at:
http://www.rodmanandrenshaw.com/conferences?id=176&link=registration

About OncoSec Medical Inc.

OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec's core technology is based upon its proprietary use of an electroporation platform, the OncoSec Medical System (OMS), to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.                                                                                                         


'/>"/>
SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
8. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
9. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
10. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
11. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... , Aug. 4, 2017 The search ... shortly after a physician/patient consult has long been the ... was a notable focus of the largest meeting of ... according to healthcare market research firm Kalorama Information.  The ... testing (POCT) offerings or related supplies and software were ...
(Date:8/3/2017)... -- Opioid addiction and other drugs of abuse, blood poisoning ... outcomes, were problems taken on directly as laboratory professionals, ... them, met this week. This according to Kalorama Information. ... abuse, procalcitonin and acute kidney injury were key focuses ... in San Diego, CA.  Mechanisms ...
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall County ... its environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The ... disinfection robot that uses UVC light energy to kill deadly pathogens such as C. ... Tru-D SmartUVC ... Tru-D in action in ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... Virsys12, ... strategic growth plans, announcing the hiring of Kevin Keelan as a Senior Account ... seasoned sales manager, Keelan will be working with Virsys12 senior leadership to extend ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... of unique masks and serums that perfectly fuse the beauty of naturally derived ... the 2017 Indie Beauty Expo on August 23rd & 24th in New York ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... the addition of Zack Tisch as the firm’s new Consulting Services Executive. Mr. ... consulting firm’s national accounts, from assisting clients with initial vendor selection and pre-implementation ...
(Date:8/22/2017)... DFW Metroplex, TX (PRWEB) , ... August 22, 2017 , ... Five Star Glass is ... They provide repair and replacement of auto glass for most makes and models, in ... area in the USA. , They have been a family owned business for the ...
(Date:8/22/2017)... ... , ... “Covert Awakening”: Walid’s spiritual journey from Islamic terrorist ... a consultant for the Intelligence Community. For more than ten years, she ... region. Julianne has written hundreds of reports for the US government analyzing ...
Breaking Medicine News(10 mins):